Keros Therapeutics (KROS) Financials

$14.30 +0.41 (+2.95%)

Closing price 04/23/2025 04:00 PM Eastern

Extended Trading

$14.30 +0.00 (+0.03%)

As of 04/23/2025 04:54 PM Eastern

Annual Income Statements for Keros Therapeutics

This table shows Keros Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	-105	-153	-187
Consolidated Net Income / (Loss)	-105	-153	-187
Net Income / (Loss) Continuing Operations	-105	-153	-187
Total Pre-Tax Income	-105	-153	-187
Total Operating Income	-115	-170	-211
Total Gross Profit	0.00	0.15	3.55
Total Revenue	0.00	0.15	3.55
Operating Revenue	0.00	0.15	3.55
Total Cost of Revenue	0.00	0.00	0.00
Total Operating Expenses	115	170	214
Selling, General & Admin Expense	28	35	41
Research & Development Expense	87	135	174
Total Other Income / (Expense), net	10	17	24
Interest Expense	0.00	0.00	0.00
Interest & Investment Income	11	15	25
Other Income / (Expense), net	-0.61	2.19	-0.95
Income Tax Expense	0.00	0.00	0.30
Basic Earnings per Share	($4.15)	($5.20)	($5.00)
Weighted Average Basic Shares Outstanding	25.24M	29.45M	37.44M
Diluted Earnings per Share	($4.15)	($5.20)	($5.00)
Weighted Average Diluted Shares Outstanding	25.24M	29.45M	37.44M
Weighted Average Basic & Diluted Shares Outstanding	28.54M	35.98M	40.56M

This table shows Keros Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	-24	-30	-36	-38	-39	-40	-43	-45	-53	-46
Consolidated Net Income / (Loss)	-24	-30	-36	-38	-39	-40	-43	-45	-53	-46
Net Income / (Loss) Continuing Operations	-24	-30	-36	-38	-39	-40	-43	-45	-53	-46
Total Pre-Tax Income	-24	-30	-36	-38	-39	-40	-43	-45	-53	-46
Total Operating Income	-28	-32	-39	-41	-43	-46	-48	-50	-59	-53
Total Gross Profit	0.00	-	0.00	0.00	0.01	0.14	0.08	0.04	0.39	3.04
Total Revenue	0.00	-	0.00	0.00	0.01	0.14	0.08	0.04	0.39	3.04
Operating Revenue	0.00	-	0.00	0.00	0.01	0.14	0.08	0.04	0.39	3.04
Total Operating Expenses	28	32	39	41	43	47	49	50	59	56
Selling, General & Admin Expense	6.94	7.09	7.78	8.80	9.15	9.11	10	9.96	9.82	11
Research & Development Expense	21	25	31	33	34	37	38	41	49	46
Total Other Income / (Expense), net	4.47	2.18	3.07	3.83	3.84	6.21	5.37	5.18	5.70	7.53
Interest & Investment Income	3.71	-	3.11	3.99	3.91	3.76	5.81	5.38	5.79	7.76
Other Income / (Expense), net	0.76	-	-0.04	-0.16	-0.07	2.46	-0.44	-0.20	-0.09	-0.23
Basic Earnings per Share	($0.92)	($1.09)	($1.26)	($1.27)	($1.33)	($1.34)	($1.21)	($1.25)	($1.41)	($1.13)
Weighted Average Basic Shares Outstanding	25.55M	25.24M	28.37M	29.60M	29.67M	29.45M	35.69M	36.10M	37.59M	37.44M
Diluted Earnings per Share	($0.92)	($1.09)	($1.26)	($1.27)	($1.33)	($1.34)	($1.21)	($1.25)	($1.41)	($1.13)
Weighted Average Diluted Shares Outstanding	25.55M	25.24M	28.37M	29.60M	29.67M	29.45M	35.69M	36.10M	37.59M	37.44M
Weighted Average Basic & Diluted Shares Outstanding	-	28.54M	29.58M	29.66M	29.96M	35.98M	36.08M	37.52M	40.51M	40.56M

This table details how cash moves in and out of Keros Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Net Change in Cash & Equivalents	49	52	229
Net Cash From Operating Activities	-70	-125	-161
Net Cash From Continuing Operating Activities	-70	-125	-160
Net Income / (Loss) Continuing Operations	-105	-153	-187
Consolidated Net Income / (Loss)	-105	-153	-187
Depreciation Expense	0.67	0.82	1.23
Amortization Expense	-	1.55	1.82
Non-Cash Adjustments To Reconcile Net Income	16	29	35
Changes in Operating Assets and Liabilities, net	18	-3.03	-10
Net Cash From Investing Activities	-1.24	-2.46	-1.93
Net Cash From Continuing Investing Activities	-1.24	-2.46	-1.93
Purchase of Property, Plant & Equipment	-1.24	-2.46	-1.93
Net Cash From Financing Activities	120	179	392
Net Cash From Continuing Financing Activities	120	179	392
Repurchase of Common Equity	-0.09	-0.09	-0.17
Issuance of Common Equity	120	176	380
Other Financing Activities, net	0.82	3.23	12

This table details how cash moves in and out of Keros Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	24	40	72	-29	-34	43	111	-37	125	29
Net Cash From Operating Activities	-25	-21	-34	-31	-34	-25	-45	-40	-31	-46
Net Cash From Continuing Operating Activities	-25	-21	-34	-31	-34	-26	-44	-39	-30	-46
Net Income / (Loss) Continuing Operations	-24	-30	-36	-38	-39	-40	-43	-45	-53	-46
Consolidated Net Income / (Loss)	-24	-30	-36	-38	-39	-40	-43	-45	-53	-46
Depreciation Expense	0.13	0.13	0.17	0.19	0.21	0.25	0.28	0.31	0.31	0.33
Amortization Expense	-	-	0.52	0.35	0.34	0.34	0.34	0.35	0.56	0.57
Non-Cash Adjustments To Reconcile Net Income	4.98	1.36	5.69	7.04	8.71	7.32	8.07	8.79	8.82	9.20
Changes in Operating Assets and Liabilities, net	-6.20	6.79	-4.73	-0.89	-4.17	6.75	-9.89	-3.66	13	-9.66
Net Cash From Investing Activities	-0.18	-0.35	-1.06	-0.31	-0.55	-0.54	-0.95	-0.31	-0.39	-0.29
Net Cash From Continuing Investing Activities	-0.18	-0.35	-1.06	-0.31	-0.55	-0.54	-0.95	-0.31	-0.39	-0.29
Purchase of Property, Plant & Equipment	-0.18	-0.35	-1.06	-0.31	-0.55	-0.54	-0.95	-0.31	-0.39	-0.29
Net Cash From Financing Activities	49	61	108	1.74	0.28	69	157	3.53	156	76
Net Cash From Continuing Financing Activities	49	61	108	1.74	0.28	69	157	3.56	156	76
Issuance of Common Equity	48	61	107	-	-	69	151	0.63	155	73
Other Financing Activities, net	0.10	0.10	0.37	1.74	0.31	0.80	5.72	2.97	1.01	2.45

This table presents Keros Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Total Assets	307	370	616
Total Current Assets	286	347	589
Cash & Equivalents	279	331	560
Accounts Receivable	0.00	0.14	2.74
Prepaid Expenses	6.72	16	26
Plant, Property, & Equipment, net	2.02	4.13	4.24
Total Noncurrent Assets	19	19	23
Other Noncurrent Operating Assets	19	19	23
Total Liabilities & Shareholders' Equity	307	370	616
Total Liabilities	29	38	44
Total Current Liabilities	17	24	27
Accounts Payable	3.34	5.45	4.60
Accrued Expenses	13	18	21
Other Current Liabilities	0.46	1.01	1.98
Total Noncurrent Liabilities	13	13	17
Other Noncurrent Operating Liabilities	13	13	17
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	277	332	572
Total Preferred & Common Equity	277	332	572
Preferred Stock	0.00	0.00	0.00
Total Common Equity	277	332	572
Common Stock	506	714	1,140
Retained Earnings	-228	-381	-569

This table presents Keros Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Total Assets	384	356	326	486	455	579
Total Current Assets	362	334	304	463	433	552
Cash & Equivalents	351	322	288	442	406	531
Accounts Receivable	-	-	-	0.23	0.00	0.39
Prepaid Expenses	11	12	17	20	27	21
Plant, Property, & Equipment, net	2.93	3.09	3.36	4.43	4.29	4.37
Total Noncurrent Assets	19	19	18	18	18	23
Other Noncurrent Operating Assets	19	19	18	18	18	23
Total Liabilities & Shareholders' Equity	384	356	326	486	455	579
Total Liabilities	29	30	30	32	34	46
Total Current Liabilities	15	16	17	19	21	29
Accounts Payable	4.68	4.15	3.87	4.99	6.54	4.98
Accrued Expenses	11	12	12	13	14	22
Other Current Liabilities	0.00	0.00	0.61	1.05	1.10	1.86
Total Noncurrent Liabilities	14	14	14	13	13	17
Other Noncurrent Operating Liabilities	14	14	14	13	13	17
Total Equity & Noncontrolling Interests	355	326	296	454	421	533
Total Preferred & Common Equity	355	326	296	454	421	533
Preferred Stock	-	-	-	0.00	0.00	0.00
Total Common Equity	355	326	296	454	421	533
Common Stock	619	628	637	878	891	1,056
Retained Earnings	-264	-302	-341	-425	-470	-523

This table displays calculated financial ratios and metrics derived from Keros Therapeutics' official financial filings.

Metric	2022	2023	2024
Growth Metrics	-	-	-
Revenue Growth	-100.00%	0.00%	2,250.99%
EBITDA Growth	-105.39%	-44.15%	-26.22%
EBIT Growth	-103.33%	-45.36%	-26.25%
NOPAT Growth	-103.63%	-48.05%	-24.06%
Net Income Growth	-78.20%	-46.15%	-22.46%
EPS Growth	-64.68%	-25.30%	3.85%
Operating Cash Flow Growth	-12.73%	-77.71%	-29.20%
Free Cash Flow Firm Growth	-15.59%	-85.45%	-30.00%
Invested Capital Growth	-112.37%	165.60%	990.24%
Revenue Q/Q Growth	0.00%	1,787.50%	445.31%
EBITDA Q/Q Growth	0.00%	-6.87%	-4.59%
EBIT Q/Q Growth	0.00%	-7.91%	-4.69%
NOPAT Q/Q Growth	0.00%	-9.32%	-3.33%
Net Income Q/Q Growth	0.00%	-7.39%	-3.19%
EPS Q/Q Growth	0.00%	-5.05%	4.03%
Operating Cash Flow Q/Q Growth	0.00%	-3.33%	-14.64%
Free Cash Flow Firm Q/Q Growth	-2,184.78%	-4.19%	-15.41%
Invested Capital Q/Q Growth	0.00%	-86.59%	440.31%
Profitability Metrics	-	-	-
Gross Margin	0.00%	100.00%	100.00%
EBITDA Margin	0.00%	-109,523.18%	-5,879.94%
Operating Margin	0.00%	-112,543.71%	-5,938.96%
EBIT Margin	0.00%	-111,090.73%	-5,965.83%
Profit (Net Income) Margin	0.00%	-101,319.21%	-5,277.55%
Tax Burden Percent	100.00%	100.00%	100.16%
Interest Burden Percent	90.71%	91.20%	88.32%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	-2,326.34%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	-2,317.42%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	2,284.88%
Return on Equity (ROE)	-40.22%	-50.19%	-41.46%
Cash Return on Invested Capital (CROIC)	0.00%	-11,411.79%	-2,492.73%
Operating Return on Assets (OROA)	0.00%	-49.57%	-42.96%
Return on Assets (ROA)	0.00%	-45.21%	-38.01%
Return on Common Equity (ROCE)	-40.22%	-50.19%	-41.46%
Return on Equity Simple (ROE_SIMPLE)	-37.73%	-46.05%	-32.78%
Net Operating Profit after Tax (NOPAT)	-80	-119	-148
NOPAT Margin	0.00%	-78,780.60%	-4,157.27%
Net Nonoperating Expense Percent (NNEP)	-9.56%	-11.15%	-8.93%
Return On Investment Capital (ROIC_SIMPLE)	-28.96%	-35.81%	-25.82%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	23,068.87%	1,148.00%
R&D to Revenue	0.00%	89,574.83%	4,890.96%
Operating Expenses to Revenue	0.00%	112,643.71%	6,038.96%
Earnings before Interest and Taxes (EBIT)	-115	-168	-212
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-115	-165	-209
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	4.46	3.59	1.12
Price to Tangible Book Value (P/TBV)	4.46	3.59	1.12
Price to Revenue (P/Rev)	0.00	7,888.64	180.63
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	806.79	7.00
Enterprise Value to Revenue (EV/Rev)	0.00	5,695.62	22.90
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00
Financial Leverage	-0.98	-1.00	-0.99
Leverage Ratio	1.08	1.11	1.09
Compound Leverage Factor	0.98	1.01	0.96
Debt to Total Capital	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00
Altman Z-Score	24.05	17.01	7.35
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	17.27	14.25	21.45
Quick Ratio	16.86	13.59	20.50
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-66	-122	-158
Operating Cash Flow to CapEx	-5,645.61%	-5,053.08%	-8,330.86%
Free Cash Flow to Firm to Interest Expense	-65,596.00	0.00	0.00
Operating Cash Flow to Interest Expense	-70,062.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	-71,303.00	0.00	0.00
Efficiency Ratios	-	-	-
Asset Turnover	0.00	0.00	0.01
Accounts Receivable Turnover	0.00	0.00	2.46
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.05	0.85
Accounts Payable Turnover	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	148.31
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	148.31
Capital & Investment Metrics	-	-	-
Invested Capital	-1.63	1.07	12
Invested Capital Turnover	0.00	-0.54	0.56
Increase / (Decrease) in Invested Capital	-15	2.69	11
Enterprise Value (EV)	958	860	81
Market Capitalization	1,237	1,191	641
Book Value per Share	$10.99	$11.09	$14.11
Tangible Book Value per Share	$10.99	$11.09	$14.11
Total Capital	277	332	572
Total Debt	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00
Net Debt	-279	-331	-560
Capital Expenditures (CapEx)	1.24	2.46	1.93
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-9.83	-8.23	1.51
Debt-free Net Working Capital (DFNWC)	269	323	561
Net Working Capital (NWC)	269	323	561
Net Nonoperating Expense (NNE)	24	34	40
Net Nonoperating Obligations (NNO)	-279	-331	-560
Total Depreciation and Amortization (D&A)	0.67	2.37	3.05
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	-5,448.34%	42.59%
Debt-free Net Working Capital to Revenue	0.00%	213,854.30%	15,815.30%
Net Working Capital to Revenue	0.00%	213,854.30%	15,815.30%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($4.15)	($5.20)	($5.00)
Adjusted Weighted Average Basic Shares Outstanding	25.24M	29.45M	37.44M
Adjusted Diluted Earnings per Share	($4.15)	($5.20)	($5.00)
Adjusted Weighted Average Diluted Shares Outstanding	25.24M	29.45M	37.44M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	28.54M	35.98M	40.56M
Normalized Net Operating Profit after Tax (NOPAT)	-80	-119	-148
Normalized NOPAT Margin	0.00%	-78,780.60%	-4,157.27%
Pre Tax Income Margin	0.00%	-101,319.21%	-5,269.10%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	-115,403.00	0.00	0.00
NOPAT to Interest Expense	-80,353.00	0.00	0.00
EBIT Less CapEx to Interest Expense	-116,644.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	-81,594.00	0.00	0.00
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	-0.08%	-0.06%	-0.09%

This table displays calculated financial ratios and metrics derived from Keros Therapeutics' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	4,750.00%	2,027.27%
EBITDA Growth	-33.89%	0.00%	-59.16%	-34.99%	-57.99%	-36.39%	-26.38%	-22.07%	-35.23%	-21.10%
EBIT Growth	-33.84%	0.00%	-61.27%	-35.41%	-59.28%	-37.67%	-25.73%	-22.04%	-35.53%	-21.56%
NOPAT Growth	-38.52%	0.00%	-61.11%	-34.53%	-54.70%	-45.35%	-24.73%	-22.02%	-35.53%	-14.64%
Net Income Growth	0.00%	0.00%	-48.04%	-37.55%	-67.77%	-35.42%	-20.42%	-20.67%	-34.27%	-14.37%
EPS Growth	0.00%	0.00%	-24.75%	-12.39%	-44.57%	-22.94%	3.97%	1.57%	-6.02%	15.67%
Operating Cash Flow Growth	-70.36%	0.00%	-2,299.09%	-36.49%	-38.13%	-18.73%	-30.16%	-29.09%	10.25%	-80.71%
Free Cash Flow Firm Growth	-56.82%	55.95%	-31.99%	-125.87%	-70.32%	-362.37%	-36.16%	-18.55%	7.80%	-35.85%
Invested Capital Growth	100.00%	-112.37%	0.00%	173.76%	0.00%	165.60%	223.60%	255.53%	-72.94%	990.24%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	1,687.50%	-41.96%	-55.42%	948.65%	684.02%
EBITDA Q/Q Growth	10.70%	-17.52%	-20.06%	-7.14%	-4.52%	-1.45%	-2.07%	-3.48%	-15.78%	9.15%
EBIT Q/Q Growth	11.19%	-17.44%	-21.74%	-6.64%	-4.47%	-1.50%	-2.12%	-3.51%	-16.02%	8.96%
NOPAT Q/Q Growth	8.96%	-14.24%	-21.62%	-6.35%	-4.70%	-7.34%	-4.37%	-4.03%	-16.29%	9.21%
Net Income Q/Q Growth	13.78%	-26.41%	-20.48%	-4.75%	-5.16%	-2.04%	-7.13%	-4.97%	-17.01%	13.09%
EPS Q/Q Growth	18.58%	-18.48%	-15.60%	-0.79%	-4.72%	-0.75%	9.70%	-3.31%	-12.80%	19.86%
Operating Cash Flow Q/Q Growth	-8.91%	12.84%	-59.66%	9.94%	-10.22%	25.08%	-75.03%	10.68%	23.37%	-50.85%
Free Cash Flow Firm Q/Q Growth	-30.35%	66.09%	-303.98%	-26.48%	1.71%	7.94%	-18.97%	-10.12%	23.55%	-35.65%
Invested Capital Q/Q Growth	100.00%	0.00%	318.77%	19.10%	87.74%	-86.59%	979.17%	30.85%	-85.71%	440.31%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	0.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	0.00%	0.00%	0.00%	0.00%	-534,950.00%	-30,361.54%	-58,197.59%	-135,089.19%	-14,915.46%	-1,728.44%
Operating Margin	0.00%	0.00%	0.00%	0.00%	-541,000.00%	-32,486.01%	-58,413.25%	-136,321.62%	-15,117.78%	-1,750.62%
EBIT Margin	0.00%	0.00%	0.00%	0.00%	-541,837.50%	-30,768.53%	-58,939.76%	-136,851.35%	-15,141.49%	-1,758.15%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	0.00%	-493,000.00%	-28,141.96%	-51,944.58%	-122,316.22%	-13,648.45%	-1,513.02%
Tax Burden Percent	100.00%	99.80%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.66%
Interest Burden Percent	86.39%	93.17%	92.02%	90.39%	90.99%	91.46%	88.13%	89.38%	90.14%	85.50%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	-762.26%	0.00%	-1,270.75%	-2,681.62%	-1,364.19%	-685.73%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	-755.91%	0.00%	-1,268.44%	-2,678.89%	-1,361.29%	-683.77%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	735.60%	0.00%	1,244.82%	2,609.74%	1,344.69%	674.17%
Return on Equity (ROE)	0.00%	-40.22%	-32.76%	-47.09%	-26.66%	-50.19%	-25.92%	-71.88%	-19.50%	-11.56%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	-5,301.16%	-2,552.51%	-2,937.76%	-11,411.79%	-1,774.85%	-1,481.61%	-2,713.38%	-2,492.73%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	0.00%	-26.57%	-13.73%	-31.70%	-91.42%	-21.77%	-12.66%
Return on Assets (ROA)	0.00%	0.00%	0.00%	0.00%	-24.18%	-12.56%	-27.93%	-81.71%	-19.62%	-10.90%
Return on Common Equity (ROCE)	0.00%	-40.22%	-32.76%	-47.09%	-26.66%	-50.19%	-25.92%	-71.88%	-19.50%	-11.56%
Return on Equity Simple (ROE_SIMPLE)	0.00%	0.00%	-32.76%	-38.78%	-48.16%	0.00%	-35.31%	-39.93%	-34.08%	0.00%
Net Operating Profit after Tax (NOPAT)	-20	-22	-27	-29	-30	-33	-34	-35	-41	-37
NOPAT Margin	0.00%	0.00%	0.00%	0.00%	-378,700.00%	-22,740.21%	-40,889.28%	-95,425.14%	-10,582.45%	-1,225.44%
Net Nonoperating Expense Percent (NNEP)	-3.55%	-2.89%	-4.89%	-3.18%	-6.35%	-2.53%	-2.31%	-2.73%	-2.91%	-1.96%
Return On Investment Capital (ROIC_SIMPLE)	-	-8.06%	-	-	-	-9.79%	-	-	-	-6.52%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	114,350.00%	6,367.13%	12,419.28%	26,921.62%	2,530.93%	350.59%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	426,750.00%	26,218.88%	46,093.98%	109,500.00%	12,686.86%	1,500.03%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	541,100.00%	32,586.01%	58,513.25%	136,421.62%	15,217.78%	1,850.62%
Earnings before Interest and Taxes (EBIT)	-27	-32	-39	-41	-43	-44	-49	-51	-59	-53
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-27	-32	-38	-41	-43	-43	-48	-50	-58	-53
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	4.46	3.43	3.64	3.20	3.59	5.25	3.92	4.09	1.12
Price to Tangible Book Value (P/TBV)	0.00	4.46	3.43	3.64	3.20	3.59	5.25	3.92	4.09	1.12
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.00	118,207.82	7,888.64	10,179.70	6,084.99	3,347.02	180.63
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	243.89	204.69	82.75	806.79	168.60	82.59	766.26	7.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	82,221.20	5,695.62	8,288.92	4,587.35	2,531.83	22.90
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.01	-0.98	-0.99	-1.00	-0.97	-1.00	-0.98	-0.97	-0.99	-0.99
Leverage Ratio	1.05	1.08	1.08	1.08	1.10	1.11	1.08	1.09	1.09	1.09
Compound Leverage Factor	0.91	1.01	1.00	0.98	1.00	1.02	0.95	0.97	0.99	0.93
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	0.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	0.00	24.94	24.61	23.24	17.82	18.11	44.39	28.28	27.64	8.20
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	0.00	17.27	23.43	20.77	18.23	14.25	24.74	20.37	19.03	21.45
Quick Ratio	0.00	16.86	22.73	20.01	17.24	13.59	23.65	19.10	18.31	20.50
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-22	-7.62	-31	-39	-38	-35	-42	-46	-35	-48
Operating Cash Flow to CapEx	-13,978.41%	-6,109.12%	-3,223.63%	-9,913.83%	-6,178.55%	-4,705.92%	-4,710.36%	-12,839.03%	-7,901.55%	-15,919.72%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.46
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.05	0.06	0.07	0.17	0.85
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	148.31
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	148.31
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	0.00	-1.63	3.56	4.23	7.95	1.07	12	15	2.15	12
Invested Capital Turnover	0.00	0.00	0.00	0.00	0.00	-0.54	0.03	0.03	0.13	0.56
Increase / (Decrease) in Invested Capital	2.87	-15	3.56	9.97	7.95	2.69	7.95	11	-5.80	11
Enterprise Value (EV)	969	958	867	867	658	860	1,940	1,243	1,648	81
Market Capitalization	969	1,237	1,218	1,189	946	1,191	2,382	1,649	2,179	641
Book Value per Share	$0.00	$10.99	$12.44	$11.03	$9.97	$11.09	$12.62	$11.66	$14.20	$14.11
Tangible Book Value per Share	$0.00	$10.99	$12.44	$11.03	$9.97	$11.09	$12.62	$11.66	$14.20	$14.11
Total Capital	0.00	277	355	326	296	332	454	421	533	572
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	0.00	-279	-351	-322	-288	-331	-442	-406	-531	-560
Capital Expenditures (CapEx)	0.18	0.35	1.06	0.31	0.55	0.54	0.95	0.31	0.39	0.29
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	-9.83	-4.67	-3.81	-0.16	-8.23	1.97	5.61	-7.65	1.51
Debt-free Net Working Capital (DFNWC)	0.00	269	347	318	288	323	444	411	523	561
Net Working Capital (NWC)	0.00	269	347	318	288	323	444	411	523	561
Net Nonoperating Expense (NNE)	3.93	7.35	8.60	8.57	9.14	7.72	9.18	9.95	12	8.75
Net Nonoperating Obligations (NNO)	0.00	-279	-351	-322	-288	-331	-442	-406	-531	-560
Total Depreciation and Amortization (D&A)	0.13	0.13	0.69	0.55	0.55	0.58	0.62	0.65	0.88	0.90
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	-1,987.50%	-5,448.34%	839.74%	2,068.63%	-1,174.35%	42.59%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	3,596,675.00%	213,854.30%	189,917.95%	151,833.58%	80,343.93%	15,815.30%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	3,596,675.00%	213,854.30%	189,917.95%	151,833.58%	80,343.93%	15,815.30%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	($1.09)	($1.26)	($1.27)	($1.33)	($1.34)	($1.21)	($1.25)	($1.41)	($1.13)
Adjusted Weighted Average Basic Shares Outstanding	0.00	25.24M	28.37M	29.60M	29.67M	29.45M	35.69M	36.10M	37.59M	37.44M
Adjusted Diluted Earnings per Share	$0.00	($1.09)	($1.26)	($1.27)	($1.33)	($1.34)	($1.21)	($1.25)	($1.41)	($1.13)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	25.24M	28.37M	29.60M	29.67M	29.45M	35.69M	36.10M	37.59M	37.44M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	28.54M	29.58M	29.66M	29.96M	35.98M	36.08M	37.52M	40.51M	40.56M
Normalized Net Operating Profit after Tax (NOPAT)	-20	-22	-27	-29	-30	-33	-34	-35	-41	-37
Normalized NOPAT Margin	0.00%	0.00%	0.00%	0.00%	-378,700.00%	-22,740.21%	-40,889.28%	-95,425.14%	-10,582.45%	-1,225.44%
Pre Tax Income Margin	0.00%	0.00%	0.00%	0.00%	-493,000.00%	-28,141.96%	-51,944.58%	-122,316.22%	-13,648.45%	-1,503.16%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	-0.08%	0.00%	0.00%	0.00%	-0.06%	0.00%	0.00%	0.00%	-0.09%

Frequently Asked Questions About Keros Therapeutics' Financials

When does Keros Therapeutics's fiscal year end?

According to the most recent income statement we have on file, Keros Therapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Keros Therapeutics' net income changed over the last 2 years?

Keros Therapeutics' net income appears to be on an upward trend, with a most recent value of -$187.35 million in 2024, rising from -$104.68 million in 2022. The previous period was -$152.99 million in 2023.

What is Keros Therapeutics's operating income?

Keros Therapeutics's total operating income in 2024 was -$210.83 million, based on the following breakdown:

Total Gross Profit: $3.55 million
Total Operating Expenses: $214.38 million

How has Keros Therapeutics revenue changed over the last 2 years?

Over the last 2 years, Keros Therapeutics' total revenue changed from $0.00 in 2022 to $3.55 million in 2024, a change of 355,000,000.0%.

How much debt does Keros Therapeutics have?

Keros Therapeutics' total liabilities were at $44.33 million at the end of 2024, a 17.2% increase from 2023, and a 51.0% increase since 2022.

How much cash does Keros Therapeutics have?

In the past 2 years, Keros Therapeutics' cash and equivalents has ranged from $279.05 million in 2022 to $559.93 million in 2024, and is currently $559.93 million as of their latest financial filing in 2024.

How has Keros Therapeutics' book value per share changed over the last 2 years?

Over the last 2 years, Keros Therapeutics' book value per share changed from 10.99 in 2022 to 14.11 in 2024, a change of 28.4%.

Related Companies

This page (NASDAQ:KROS) was last updated on 4/24/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Keros Therapeutics (KROS) Financials

Frequently Asked Questions About Keros Therapeutics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Keros Therapeutics (KROS) Financials

Annual Income Statements for Keros Therapeutics

Quarterly Income Statements for Keros Therapeutics

Annual Cash Flow Statements for Keros Therapeutics

Quarterly Cash Flow Statements for Keros Therapeutics

Annual Balance Sheets for Keros Therapeutics

Quarterly Balance Sheets for Keros Therapeutics

Annual Metrics and Ratios for Keros Therapeutics

Quarterly Metrics and Ratios for Keros Therapeutics

Frequently Asked Questions About Keros Therapeutics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools